Showing results (41-50 of 81) with videos related to
Sort By:
Pageof 9
JAMA Cardiology|December 13, 2018
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial DataArman Qamar, Robert P Giugliano, Anthony C Keech, et al.JAMA Cardiology|August 14, 2020
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical TrialPrakash Deedwania, Sabina A Murphy, Andre Scheen, et al.European Heart Journal|September 19, 2021
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trialKazuma Oyama, Robert P Giugliano, Minao Tang, et al.Circulation|April 21, 2025
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER TrialAndre Zimerman, Ana Laura F Kunzler, Brittany N Weber, et al.Journal of the American College of Cardiology|September 13, 2008
Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudyAndrew Sharp, Robyn Tapp, Darrel P Francis, et al.Circulation. Cardiovascular Quality and Outcomes|May 14, 2016
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes StudyLotte Kaasenbrood, Neil R Poulter, Peter S Sever, et al.Diabetes Care|April 28, 2005
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)Peter S Sever, Neil R Poulter, Björn Dahlöf, et al.Journal of Hypertension|October 16, 2008
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetesJan Ostergren, Neil R Poulter, Peter S Sever, et al.JAMA Cardiology|November 9, 2017
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical TrialRobert P Giugliano, Anthony Keech, Sabina A Murphy, et al.Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.Pageof 9